Cancer cachexia
Open Access
- 7 October 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 98 (11) , 779-788
- https://doi.org/10.1093/qjmed/hci127
Abstract
Cancer cachexia is a severe debilitating disorder for which there are currently few therapeutic options. It is driven by the release of pro-inflammatory cytokines and cachectic factors by both host and tumour. Over the past few years, basic science advances have begun to reveal the breadth and complexity of the immunological mechanisms involved, and in the process have uncovered some novel potential therapeutic targets. The effectiveness of thalidomide and eicosapentaenoic acid at attenuating weight loss in clinical trials also provides a further rationale for modulating the immune response. We are now entering an exciting period in cachexia research, and it is likely that the next few years will see effective new biological therapies reach clinical practice.Keywords
This publication has 75 references indexed in Scilit:
- Degradation of MyoD Mediated by the SCF (MAFbx) Ubiquitin LigaseJournal of Biological Chemistry, 2005
- Interferon-γ polymorphisms correlate with duration of survival in pancreatic cancerHuman Immunology, 2004
- Cachexia in cancer patientsNature Reviews Cancer, 2002
- Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?The Annals of Thoracic Surgery, 2001
- Cancer cachexiaSurgical Oncology, 1999
- Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia modelFEBS Letters, 1998
- Should cancer patients with incurable disease receive parenteral or enteral nutritional support?European Journal Of Cancer, 1998
- Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancerCancer, 1998
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexiaEuropean Journal of Cancer and Clinical Oncology, 1991